“The notion that public-private collaboration is inherently problematic doesn’t align with current realities. Not only is it possible—it is necessary, beneficial, and more straightforward than many assume.”
Under the banner “Bridging Research and Care for Patients,” discussions delved into targeted newborn screening programs, advanced clinical trials, and innovative translational reçsearch platforms.
Irene Norstedt: “The EU supports collaboration because no country alone, and no stakeholder alone, has the answer for such huge unmet needs in rare disease research”
